A number of risk factors for developing AML have been identified, including: other blood disorders, chemical exposures, ionizing radiation, and genetics.
Treatment of AML consists primarily of chemotherapy, and is separated into two phases: induction and postremission (or consolidation) therapy. The goal of induction therapy is to attain a complete remission by reducing the amount of leukemic cells to an unnoticeable level; the goal of consolidation therapy is to eliminate any residual undetectable disease and achieve a cure.
Acute myeloid leukemia (AML), also known as acute myelogenous leukemia, is a cancer of the myeloid line of blood cells, characterized by the rapid increase of abnormal white blood cells that accumulate in the bone marrow and get in the way with the production of normal blood cells. AML is the most common acute leukemia affecting adults, and its occurrence increases with age.